AptarGroup (ATR) Set to Release Quarterly Earnings on Thursday

AptarGroup (NYSE:ATR) is expected to issue its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $1.47 per share and revenue of $980.76 million for the quarter. AptarGroup has set its Q3 2026 guidance at 1.450-1.530 EPS. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, October 30, 2026 at 9:00 AM ET.

AptarGroup (NYSE:ATR) last posted its earnings results on Thursday, July 30th. The industrial products company reported $1.42 EPS for the quarter, topping the consensus estimate of $1.35 by $0.07. The business had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.01 billion. AptarGroup’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.66 earnings per share. On average, analysts expect AptarGroup to post $5.47 EPS for the current fiscal year and $6.14 EPS for the next fiscal year.

AptarGroup Stock Performance

Shares of NYSE ATR opened at $126.63 on Wednesday. The stock’s 50-day simple moving average is $125.93 and its two-hundred day simple moving average is $126.89. AptarGroup has a twelve month low of $103.23 and a twelve month high of $146.91.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ATR. UBS Group started coverage on AptarGroup in a research report on Friday, October 9th. They set a “neutral” rating and a $135.00 price target for the company. Weiss Ratings restated a “hold (c)” rating on shares of AptarGroup in a research report on Monday, September 21st. Raymond James Financial restated an “outperform” rating and issued a $160.00 price objective on shares of AptarGroup in a research report on Wednesday, July 15th. Bank of America raised shares of AptarGroup from a “neutral” rating to a “buy” rating and set a $173.00 target price on the stock in a research note on Tuesday, July 14th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of AptarGroup in a research report on Wednesday, October 7th. They set a “buy” rating and a $150.00 target price for the company. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, AptarGroup presently has an average rating of “Moderate Buy” and an average price target of $164.14.

Insider Activity at AptarGroup

In other AptarGroup news, CEO Stephan B. Tanda sold 9,838 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $136.16, for a total transaction of $1,339,542.08. Following the sale, the chief executive officer owned 238,729 shares in the company, valued at $32,505,340.64. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Shiela Vinczeller sold 765 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $130.37, for a total value of $99,733.05. Following the sale, the insider owned 26,313 shares in the company, valued at $3,430,425.81. The trade was a 2.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 23,197 shares of company stock valued at $3,134,828 over the last ninety days. 0.73% of the stock is currently owned by insiders.

AptarGroup Company Profile

AptarGroup, Inc (NYSE: ATR) develops and manufactures dispensing, sealing and delivery systems for the pharmaceutical, beauty, personal care, food and beverage markets. Its products are designed to control, protect and dispense a wide range of liquids, creams, lotions, fragrances and other formulations.

The company’s offerings include pumps, valves, closures, aerosol systems and other dispensing components, as well as drug-delivery technologies. Through its pharmaceutical business, Aptar supports nasal, pulmonary, ophthalmic, dermal and injectable applications, serving pharmaceutical and biotechnology companies with components and systems used in prescription, over-the-counter and consumer health products.

Aptar serves customers internationally through manufacturing, research and development and commercial operations across North America, Europe, Asia and other global markets.